Dialogue with lecturers at CE

Publication
Article
Optometry Times JournalOptometry Times Vol. 10 No. 11
Volume 10
Issue 11

Last month, I had the opportunity to lecture alongside my friend and fellow Optometry Times Editorial Advisory Board member Michael Chaglasian, OD, FAAO. We presented a two-hour glaucoma update to a wonderful audience of fellow doctors of optometry at SUNY’s Envision Conference in New York City.

I spoke on the structure-function relationship in glaucoma with respect to newer diagnostic devices and progression algorithm software as well as pressure-independent risk factors.

Dr. Chaglasian spoke on tonometry with respect to standards of care and newer devices-both for measurement in-office and at home-and contemporary means of determining the presence or absence of progression in glaucoma.

One aspect of this particular lecture that really stood out to me was the fact that we had questions-great questions-from the audience.

Audience questions
One person picked Dr. Chaglasian’s brain regarding newer non-contact tonometry devices, and his questions opened up into a great conversation about how we check intraocular pressure (IOP) on glaucoma patients for whom Goldmann tonometry is not possible.

Another member of the audience brought up that he had several patients with sleep apnea who also had retinal nerve fiber layer defects. This led to great dialogue concerning risk factors for glaucoma other than ocular hypertension.

I don’t know that it was just an engaging presentation on our part. I’d like to think so, but several examples come to mind of people being let’s just say less than engaged during a few of my lectures over the years. For whatever reason, however, the audience engagement was fantastic, and those two hours were as much of a conversational nature to a lecture as I have experienced as a speaker.

In a solo lecture later that same day, I was going over why it’s not a good idea to taper oral antibiotics with respect to drug resistance, and an audience member asked me why we may slowly taper doxycycline when treating meibomian gland dysfunction (MGD) if we’re not supposed to taper oral antibiotics.

In the years that I have given that lecture, I have never had that question come up before. It gave me the opportunity to verbally hash through the answer and to explain that this modality of treating MGD is not geared toward killing bacteria but rather toward making use of a different property of tetracyclines. I’d never really thought that particular question through, and I’m glad someone gave me the opportunity to do that.

So, please continue to ask lecturers questions and challenge us. Many of the most productive lectures I have been a part of, both as a speaker and an audience member, have been conversational in nature. Those speaking and those listening should both embrace that concept.

Discourse, dialogue, challenge, and argumentation are all good things because they exemplify why we don’t simply do optometry-we practice it.

Read more from Benjamin P. Casella, OD, FAAO.

Recent Videos
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr. Ben Casella highlights the importance of SECO to the optometric community.
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Dr Ben Gaddie chats about his dry eye presentation at SECO and ocular surface disease.jpg
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Dr. Julie Rodman previews her SECO presentations
Alysse Henkel, vice president of Research and inSights at The Vision Council, advised that expanding budget and mid-market frame options may help improve frames sales.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
© 2025 MJH Life Sciences

All rights reserved.